ACE2 and heart failure: Rising soluble ACE2 levels correlated with worsening symptoms, B-type natriuretic peptide levels and mortality in patients with heart failure (Garcia-Escobar et al., 2021), and the sum of Ang 1–7 and Ang 1–5 concentrations as marker of alternative RAS activation predicted adverse events in patients with heart failure and preserved ejection fraction (Binder et al., 2019).